a, a N Clinical Trials

A listing of a, a N clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20588 clinical trials
Featured trial
 
Visit this <a href="https://picnichealth.com/sickle-cell-disease-100?utm_source=partner&utm_medium

Online studies
  • 11 views
  • 04 Aug, 2022
  • 1 location
  • Online study
Featured trial
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of single-agent INCB081776 (Part 1) and INCB081776 in combination with INCMGA00012 (Part 2).

  • 0 views
  • 08 Jul, 2022
  • 11 locations
Featured trial
A Trial Evaluating Different Dosing Durations of TEPEZZA® Treatment in Patients with Thyroid Eye Disease (TED)

The overall objective is to investigate the safety, tolerability and need for re-treatment of 3 different TEPEZZA® treatment durations (4, 8, or 16 infusions) in patients with TED.

  • 8 views
  • 23 Jul, 2022
  • 10 locations
Featured trial
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early

early parkinson's
dopamine transporter
SPECT Scan
dopamine
tremor
  • 151 views
  • 28 Jul, 2022
  • 103 locations
Featured trial
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

Welcome to TogetherA study for memory loss If you are concerned about changes to your memory, joining the Together

mild cognitive impairment
amyloid
cognitive impairment
mental state examination
mini-mental state examination
  • 65 views
  • 29 Jul, 2022
  • 86 locations
Featured trial
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

<a href="https://www.myelofibrosisresearch.com/CW/" target="_blank">www.MyelofibrosisResearch.coma>

Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts

  • 380 views
  • 10 Jul, 2022
  • 150 locations
Featured trial
Study to evaluate HZN-825 in patients with Idiopathic Pulmonary Fibrosis (IPF)

daily (QD) or twice daily (BID)) or a placebo regimen for 52 weeks. Participants who complete the duration of this trial may be eligible to enter an open-label 52-week extension trial where all patients

diffusion capacity of the lung for carbon monoxide
emphysema
pneumonia
  • 8 views
  • 14 Jul, 2022
  • 20 locations
Featured trial
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

<a href="https://www.myelofibrosisresearch.com/CW/" target="_blank">www.MyelofibrosisResearch.coma>

Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the

  • 833 views
  • 23 Jul, 2022
  • 226 locations
Featured trial
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously

  • 1245 views
  • 30 Jun, 2022
  • 84 locations
Featured trial
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously

  • 10 views
  • 30 Jun, 2022
  • 81 locations